Published in J Clin Invest on November 09, 2009
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood (2011) 1.67
Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease. Stem Cell Res Ther (2015) 1.40
A motif in the V3 domain of the kinase PKC-θ determines its localization in the immunological synapse and functions in T cells via association with CD28. Nat Immunol (2011) 1.30
Acute graft-versus-host disease: a bench-to-bedside update. Blood (2014) 1.23
Antigen-presenting cell-derived complement modulates graft-versus-host disease. J Clin Invest (2012) 1.09
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance. J Clin Invest (2013) 1.08
PKC-θ function at the immunological synapse: prospects for therapeutic targeting. Trends Immunol (2011) 1.06
PKC-theta-mediated signal delivery from the TCR/CD28 surface receptors. Front Immunol (2012) 0.97
Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. Blood (2013) 0.96
MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. Blood (2015) 0.94
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease. Blood (2013) 0.88
The yin and yang of protein kinase C-theta (PKCθ): a novel drug target for selective immunosuppression. Adv Pharmacol (2013) 0.87
Biology of graft-versus-host responses: recent insights. Biol Blood Marrow Transplant (2013) 0.86
Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. PLoS One (2015) 0.86
From innate to adaptive immune response in muscular dystrophies and skeletal muscle regeneration: the role of lymphocytes. Biomed Res Int (2014) 0.85
CRK proteins selectively regulate T cell migration into inflamed tissues. J Clin Invest (2015) 0.84
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest (2016) 0.83
T-bet is critical for the development of acute graft-versus-host disease through controlling T cell differentiation and function. J Immunol (2014) 0.82
Intervention of PKC-θ as an immunosuppressive regimen. Front Immunol (2012) 0.82
The role of protein kinase cη in T cell biology. Front Immunol (2012) 0.80
Targeting PKCθ in alloreactivity and graft-versus-host-disease: unanswered questions and therapeutic potential. Front Immunol (2012) 0.80
PKC-θ: hitting the bull's eye. Nat Immunol (2011) 0.80
Bim is required for T-cell allogeneic responses and graft-versus-host disease in vivo. Am J Blood Res (2012) 0.80
Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens. Cancer Immunol Immunother (2010) 0.80
Protein kinase C inhibitors for immune disorders. Drug Discov Today (2014) 0.79
Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation. Cell Rep (2015) 0.79
Embryonic stem cell-derived factors inhibit T effector activation and induce T regulatory cells by suppressing PKC-θ activation. PLoS One (2012) 0.79
Intracellular Delivery of Anti-pPKCθ (Thr538) via Protein Transduction Domain Mimics for Immunomodulation. Mol Ther (2016) 0.78
The Novel PKCθ from Benchtop to Clinic. J Immunol Res (2015) 0.78
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res (2016) 0.78
PKC-Theta in Regulatory and Effector T-cell Functions. Front Immunol (2015) 0.77
NF-κB is crucial in proximal T-cell signaling for calcium influx and NFAT activation. Eur J Immunol (2014) 0.76
Doubling down on PKC benefits allogeneic BMT. Blood (2013) 0.76
PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. Breast Cancer Res (2016) 0.75
T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice. J Immunol (2016) 0.75
IKKβ-induced inflammation impacts the kinetics but not the magnitude of the immune response to a viral vector. Eur J Immunol (2012) 0.75
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. Viruses (2016) 0.75
T cell receptor antagonist peptides induce positive selection. Cell (1994) 18.66
The B7 family revisited. Annu Rev Immunol (2005) 13.51
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood (2004) 7.09
PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature (2000) 5.48
Graft-versus-host disease. Nat Rev Immunol (2007) 4.26
Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature (1988) 4.02
Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol (2001) 3.95
Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature (1988) 3.82
CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med (2002) 3.70
Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol (2007) 3.65
Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis (1986) 3.31
Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med (2004) 2.89
T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science (1994) 2.81
Protein kinase C(theta) in T cell activation. Annu Rev Immunol (2002) 2.68
Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood (2008) 2.53
Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med (2003) 2.30
Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J Exp Med (2002) 2.14
Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med (2003) 1.93
Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant (1999) 1.90
Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J Exp Med (2004) 1.88
A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med (2005) 1.88
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008) 1.82
Protein kinase C and beyond. Nat Immunol (2004) 1.79
LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood (2003) 1.67
Differential requirement of PKC-theta in the development and function of natural regulatory T cells. Mol Immunol (2008) 1.63
Altered peptide ligands induce delayed CD8-T cell receptor interaction--a role for CD8 in distinguishing antigen quality. Immunity (2006) 1.63
CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. Proc Natl Acad Sci U S A (1992) 1.61
Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood (2005) 1.51
Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood (2001) 1.46
CCR2 is required for CD8-induced graft-versus-host disease. Blood (2005) 1.43
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med (2002) 1.35
Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev (1997) 1.24
Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood (2007) 1.23
The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression. Immunity (2004) 1.22
Protein kinase Ctheta controls Th1 cells in experimental autoimmune encephalomyelitis. J Immunol (2005) 1.21
Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A (2005) 1.21
CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood (2005) 1.19
Lack of essential role of NF-kappa B p50, RelA, and cRel subunits in virus-induced type 1 IFN expression. J Immunol (2007) 1.19
PKC-theta selectively controls the adhesion-stimulating molecule Rap1. Blood (2008) 1.18
T-cell fate and function: PKC-theta and beyond. Trends Immunol (2008) 1.17
Protein kinase C-theta is an early survival factor required for differentiation of effector CD8+ T cells. J Immunol (2005) 1.17
Signal 3 availability limits the CD8 T cell response to a solid tumor. J Immunol (2007) 1.16
PKCtheta signals activation versus tolerance in vivo. J Exp Med (2004) 1.15
In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res (2008) 1.14
PKC-theta-deficient mice are protected from Th1-dependent antigen-induced arthritis. J Immunol (2006) 1.13
TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-theta signaling and promote autoimmune myocarditis. J Immunol (2007) 1.10
CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol (2000) 1.07
Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro. J Exp Med (1996) 1.04
Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells. J Immunol (2006) 1.01
Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. J Immunol (2006) 1.00
CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. Blood (2007) 0.98
Protein kinase C activity is required for cytotoxic T cell lytic granule exocytosis, but the theta isoform does not play a preferential role. J Leukoc Biol (2006) 0.98
A critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection. J Immunol (2008) 0.97
Chronic GvHD decreases antiviral immune responses in allogeneic BMT. Blood (2007) 0.96
The critical role of protein kinase C-theta in Fas/Fas ligand-mediated apoptosis. J Immunol (2007) 0.96
CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. J Immunol (2000) 0.93
Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. J Immunol (2008) 0.90
Protein kinase C-theta critically regulates the proliferation and survival of pathogen-specific T cells in murine listeriosis. J Immunol (2008) 0.90
Principles of antimicrobial therapy in the transplant patient. Transpl Infect Dis (2004) 0.88
Visualization, fate, and pathogenicity of antigen-specific CD8+ T cells in the graft-versus-host reaction. J Immunol (1999) 0.81
The persistent challenges of bacterial infections in the transplant recipient. Transpl Infect Dis (2006) 0.76
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem (2003) 15.88
Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (2003) 9.67
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Effector and memory CTL differentiation. Annu Rev Immunol (2007) 7.17
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood (2004) 7.09
CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol (2004) 6.80
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 6.45
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med (2004) 6.26
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature (2006) 5.90
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 5.72
IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol (2007) 5.31
Cytokine requirements for acute and Basal homeostatic proliferation of naive and memory CD8+ T cells. J Exp Med (2002) 5.09
Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity (2010) 4.52
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Complete but curtailed T-cell response to very low-affinity antigen. Nature (2009) 4.31
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77
Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc Natl Acad Sci U S A (2010) 3.68
Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol (2007) 3.65
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood (2009) 3.62
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood (2003) 3.42
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science (2010) 3.31
Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med (2004) 3.30
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant (2002) 3.29
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med (2007) 3.21
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol (2004) 3.10
Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06
Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model (2010) 3.04
T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity (2006) 3.02
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol (2010) 2.99
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol (2004) 2.84
Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med (2010) 2.82
Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. Nature (2011) 2.75
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood (2004) 2.63
In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med (2003) 2.59
Rapid culling of the CD4+ T cell repertoire in the transition from effector to memory. Immunity (2008) 2.56
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol (2008) 2.55
Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood (2008) 2.53
Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med (2004) 2.50
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J Immunol (2003) 2.47
CD8(+) T cells: foot soldiers of the immune system. Immunity (2011) 2.45
Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded. Tissue Eng Part A (2010) 2.44
Positive selection of MHC class Ib-restricted CD8(+) T cells on hematopoietic cells. Nat Immunol (2002) 2.40
IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog (2010) 2.39
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood (2008) 2.34
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med (2002) 2.32
Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity (2002) 2.31
Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol (2005) 2.31
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood (2004) 2.28
The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens. Nat Immunol (2003) 2.26
Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells (2010) 2.25
Acute graft-versus-host disease: from the bench to the bedside. Blood (2009) 2.24
In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood (2008) 2.24
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 2.23
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol (2010) 2.20
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res (2010) 2.19
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med (2013) 2.18
Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD8+ T cell response. J Exp Med (2006) 2.18
Leukocyte migration and graft-versus-host disease. Blood (2005) 2.17
CD8alpha+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo. J Immunol (2005) 2.16
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood (2007) 2.12
Shortening the infectious period does not alter expansion of CD8 T cells but diminishes their capacity to differentiate into memory cells. J Immunol (2004) 2.09
Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev (2008) 2.07
Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res (2007) 2.06
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 2.03
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 2.03
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01
Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol (2012) 1.98
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood (2003) 1.97
Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood (2011) 1.97
Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging (2004) 1.97
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005) 1.95
Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med (2003) 1.93
Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood (2006) 1.92
Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry (2005) 1.92